Bio-Path stock: buy or sell?

BPTH stock price: $15.19 1.13% At close on May 21st, 2019

Updated on:
May 21st, 2019

0

After sliding for 4 sessions, Tuesday Bio-Path raised a fine 1.13%, closing at $15.19. On May 14th BPTH boosted an astounding 18.17%. On Friday BPTH plunged a chilling -7.92%. Tuesday session broke a read streak of 4 sessions in a row.

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development company in the United States.

Should I buy Bio-Path stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Following a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

Currently, Bio-Path stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean BPTH will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Bio-Path stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. Unfortunately, we couldn't find any rating for BPTH stock for the last 30 days.

Bio-Path stock analysis

Daily outlook

After sliding for 4 sessions, Tuesday Bio-Path raised a fine 1.13%, closing at $15.19.

After sliding for 4 sessions, Tuesday Bio-Path raised a fine 1.13%, closing at $15.19. BPTH is retaking the upward trend marking a new rising bottom heading to break out over $19.00. Since SMA50d and SMA100d crossed up on March, BPTH price slid a -45.34%.

BPTH stock chart (daily)

Weekly outlook

Bio-Path shares slightly fell -2.19% this week, ending at $15.19. By mid April BPTH rocketed an amazing 17.72% in just one week. For 5 weeks in a row, price slid and lost a -24.47%. Early May BPTH plummed a chilling -5.51% in just one week.

Since SMA20w and SMA40w crossed up this week, BPTH price slid a -2.19%. Since early March when BPTH stock price broke up the SMA40w line, it gained $7.47 (96.76%).

BPTH stock chart (weekly)

Bio-Path stock price history

Bio-Path stock went public on March 15th, 2010 with a price of $100.001. Since then, BPTH stock lost a -84.80%, with a yearly average of -9.40%.

1: Adjusted price after possible price splits or reverse-splits.

Bio-Path stock historical price chart

BPTH stock reached 52-week highs on March at $73.52, and all-time highs 2014-01-03 with a price of 1050.

Bio-Path stock price target

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we have not detected any price forecast for Bio-Path stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

After publishing its last earnings report on March, Bio-Path collapsed a hair-raising -39.72%. As soon as we get its actual EPS from the earnings report, we will extend this report.
BPTH earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.04n/a
2017-Q2-n/a-0.26n/a
2017-Q32017-11-09-0.2-0.2n/a
2017-Q42018-04-03n/an/an/a
2018-Q12018-05-16n/a-0.17n/a
2018-Q22018-08-15n/a-0.15n/a
2018-Q32018-11-15n/a-0.27n/a
2018-Q42019-03-20n/an/an/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

In 2017, Bio-Path annual turnover climbed a super good 184.62% to $0.04 M dollars from $0.01 marked in 2016. When comparing 2017 vs 2016, likewise, profit margin (that is, the net income divided by revenues) rocketed a 32,942.00% to -18,981.08%.

BPTH annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2016$0.01 M-$-6.75 M-51923.1%-
2017$0.04 M184.62%$-7.02 M-18981.1%4.04%

Quarterly financial results

Reported quarter income marked $-1.91 M with a profit margin of . Profit margin remained stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing revenues to same quarter last year, Bio-Path sales marked a frightening decrease and plummed a -100.00%. Looking back to recent quarterly results, Bio-Path posted 4 positive quarters in a row.
BPTH quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q4$0.04 M-$-2.17 M-5856.8%-

Bio-Path ownership

When you are planning to invest in shares of a stock, it's always worth to have a look its ownership structure.

Bio-Path shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 5.62% of all shares.

In case of Bio-Path stock, 28.47% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for BPTH stock account 0.00%, no big difference from last month.

For a better context understanding, the following table shows ownership data compared to other related stocks:

BPTH
Market cap$38.1 M
Total shares2.5 M
Float shares2.1 M
  - Institutional holdings (%)28.5%
  - Insider holdings (%)5.6%
Shares in short selling0.0%

Bio-Path summary

Tuesday, May 21st, 2019
Open$15.00
Close$15.19
Day range$15.00 - $15.63
Previous close$15.02
Session gain1.13%
Average true range$1.28
50d mov avg$19.30
100d mov avg$12.02
200d mov avg$14.11
Daily patternlb02a
Weekly pattern lt11c

Bio-Path performance

To measure stock performance is always good to benchmark with competitors or related stocks. We selected as the bechmarking frame for Bio-Path stock.
Stock3m6m12m
BPTHBio-Path590.45%40.65%-57.09%

Bio-Path competitors

Unfortunately, we could not find any public company that could be defined as Bio-Path competitor. This doesn't mean Bio-Path does not have any competitor in the market, it's just we could not detected it.